Longeveron Inc is a biotechnology company focused on developing cellular therapies to address age-related and life-threatening conditions
The company specializes in the research and commercialization of innovative treatments, particularly those utilizing mesenchymal stem cells derived from umbilical cord tissue. Longeveron aims to improve the quality of life for patients suffering from diseases such as Alzheimer’s and cardiac dysfunction by harnessing the potential of these advanced therapies to promote regeneration and improve overall health outcomes. Through its commitment to scientific research and clinical trials, Longeveron is at the forefront of modern medicine, exploring new avenues for healing and enhancing longevity.
A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here's a look at the others.
Longeveron presented promising Phase 2a clinical trial data for Lomecel-B at the AAIC 2024. The trial showed the drug's safety and efficacy in treating Alzheimer's, demonstrating slowed disease progression, improved daily living activities, and minimized brain volume loss.
Longeveron shares are trading lower by 15.9% during Thursday's session. The company announced a $9.0 million registered direct offering of 2.2 million shares of its common stock.
